ARTL · XBRL financial data

Artelo Biosciences financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARTL's year ends in late December)

In thousands of dollars	FY 2021Aug 31, 2021	FY 2022Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	2,839	3,784	4,324	5,696	5,993	5,423
General and administrative	3,521	5,633	5,963	4,234	4,115	5,981
Total operating expenses	7,441	9,417	10,287	9,930	10,108	11,404
Operating income (loss)	(7,441)	(9,417)	(10,287)	(9,930)	(10,108)	(11,404)
Interest expense	0	—	5	0	0	194
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(7,437)	(9,407)	(10,083)	(9,289)	(9,826)	(12,879)
Earnings per share, diluted USD per share	—	—	—	(3.14)	(3.05)	(12.52)
Weighted average shares, diluted thousands of shares	—	—	—	2,960	3,223	1,029

† Share count changed about 1/15 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ARTL's year ends in late December)

In thousands of dollars	FY 2021Aug 31, 2021	FY 2022Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	6,629	12,162	6,888	2,815	2,338	600
Marketable securities	3,436	11,951	9,150	7,611	0	—
Marketable securities, non-current	3,436	11,951	9,150	7,611	0	—
Prepaid and other current assets	189	3	789	554	219	95
Total current assets	10,317	24,609	18,322	10,980	2,557	695
Right-of-use asset	90	81	60	21	99	64
Total assets	12,635	28,251	20,424	13,043	4,698	2,801
Accrued liabilities	—	—	—	—	0	11
Total current liabilities	526	1,027	998	1,291	1,772	4,044
Lease liability, non-current	67	57	23	0	69	29
Total liabilities	593	1,084	1,021	1,291	1,841	4,073
Accumulated deficit	(16,903)	(20,938)	(31,021)	(40,310)	(50,136)	(63,015)
Total stockholders' equity	12,042	27,167	19,403	11,752	2,857	(1,272)
Total liabilities and equity	12,635	28,251	20,424	13,043	4,698	2,801
Common shares outstanding (cover page) thousands of shares	42,301	42,301	2,856	3,228	3,281	2,125

† Share count changed about 1/15 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ARTL's year ends in late December)

In thousands of dollars	FY 2021Aug 31, 2021	FY 2022Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,437)	(9,407)	(10,083)	(9,289)	(9,826)	(12,879)
Stock-based compensation	1,531	—	2,458	1,020	818	1,142
Net cash from operating activities	(6,141)	—	(8,008)	(8,207)	(8,350)	(8,520)
Net cash from investing activities	(3,439)	—	2,958	3,507	7,769	(62)
Proceeds from issuing common stock	8,103	—	0	567	112	6,151
Proceeds from issuing equity	—	—	—	—	—	75,000
Net cash from financing activities	14,112	—	0	567	112	6,867
Net change in cash	4,487	—	(5,274)	(4,073)	(477)	(1,738)

† Share count changed about 1/15 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.